Close Menu

NEW YORK – Alzheimer's diagnostics firm C2N said Thursday it has received a $20 million investment from philanthropic organization GHR Foundation.

St. Louis-based C2N said it will use the funds to build out its CLIA facility and position its blood-based Alzheimer's disease diagnostic test, called APTUS-Aβ, for the clinic. The company is currently working to secure US Food and Drug Administration 510(k) clearance for the test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.